- Home
- VYNE vs ITRM Comparison
VYNE vs ITRM Comparison
Compare VYNE & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | ITRM |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.3M | 24.3M |
| IPO Year | 2017 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VYNE | ITRM |
|---|---|---|
| Price | $0.66 | $0.03 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 144.2K | ★ 30.9M |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 33.33 | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.29 | $0.03 |
| 52 Week High | $1.96 | $1.16 |
Technical Indicators
Market Signals| Indicator | VYNE | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.99 | 26.10 |
| Support Level | $0.56 | N/A |
| Resistance Level | $0.69 | $0.39 |
| Average True Range (ATR) | 0.02 | 0.02 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 49.10 | 3.34 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.